Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?

RT @jleePSOC: Great piece on the importance of advancing current thinking of #adverseevents to improve #qualityoflife in long term #cancers…

RT @SeanKhozin: We have an opportunity to modernize #adverseevent reporting from early stage to postmaket/survivorship; because: 1. Most ex…

RT @stage4kelly: #1 HOORAY for open access & being able to read the entire article!! #2 if patients are involved from the get-go, trials wi…

RT @stage4kelly: #1 HOORAY for open access & being able to read the entire article!! #2 if patients are involved from the get-go, trials wi…

RT @SeanKhozin: We have an opportunity to modernize #adverseevent reporting from early stage to postmaket/survivorship; because: 1. Most ex…

RT @SeanKhozin: We have an opportunity to modernize #adverseevent reporting from early stage to postmaket/survivorship; because: 1. Most ex…

#1 HOORAY for open access & being able to read the entire article!! #2 if patients are involved from the get-go, trials will be better b/c metrics important to us will be included. #3 trials should be more representative of the population who'll be usi

RT @jleePSOC: Great piece on the importance of advancing current thinking of #adverseevents to improve #qualityoflife in long term #cancers…

RT @jleePSOC: Great piece on the importance of advancing current thinking of #adverseevents to improve #qualityoflife in long term #cancers…

RT @SeanKhozin: We have an opportunity to modernize #adverseevent reporting from early stage to postmaket/survivorship; because: 1. Most ex…

RT @jleePSOC: Great piece on the importance of advancing current thinking of #adverseevents to improve #qualityoflife in long term #cancers…

RT @jleePSOC: Great piece on the importance of advancing current thinking of #adverseevents to improve #qualityoflife in long term #cancers…

We have an opportunity to modernize #adverseevent reporting from early stage to postmaket/survivorship; because: 1. Most expedited safety reports sent to FDA are uninformative https://t.co/DWhHGimbZi 2. Hi tech solutions are possible & paradigm changin

Great piece on the importance of advancing current thinking of #adverseevents to improve #qualityoflife in long term #cancersurvivors by @HESI_Global & @HESITHRIVE leader Syril Pettit @chemobrainfog @stales @stage4kelly @Stigetta #forpatientbenefit